Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (960)	7/5/1998 1:08:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Ed, My recollection is that Dan refused to believe the SEPR trials that showed lung function after long term albuterol use was worse than a placebo, and much worse than levalbuterol. Hence the importance of the new trial SEPR is running to attempt to demonstrate conclusively that levalbuterol's advantage over albuterol is not just fewer immediate side-effects but also long-term improved lung function. Peter

To: Ed Ajootian who wrote (960)	7/5/1998 8:29:00 PM
From: billy d	Respond to of 10280

Nothing personal against Dan but I think his best shot at the low 20's will be a 3 for 1 split at 70 bucks.

To: Ed Ajootian who wrote (960)	7/6/1998 1:58:00 PM
From: Thomas M.	Respond to of 10280

I remember that well. Dan was confusing his roles as physician and investor. The evidence has been there for a long time that Levalbuterol will show a much better side effect profile. He was waiting for conclusive proof, which will probably be published around when SEPR hits 100. <g> Tom

To: Ed Ajootian who wrote (960)	7/6/1998 10:28:00 PM
From: bazer	Read Replies (2) \| Respond to of 10280

Ed, Dr.Dan doesn't act like any of the pulmonary docs I know. When presented with the clinical studies results they will be demanding this drug. Cost will not be that big a factor! One of the most discouraging things is when you see a patient with end stage COPD. It gets to the point where Albuterol really doesn't do anything for them, doesn't open the airways and they sometimes even refuse it. Meanwhile their pulmonary function studies show decreased flow rates and less functioning lung area. Levalbuterol has to be better than Albuterol as shown in all the trials. Also what about Peds? The babies and kids get better bronchodilation at half the standard dosage of Albuterol! The Peds pulmonary docs are going to love this and Dr. Dan will soon be ordering it. As for his comments about nonsedating antihistamines Sepracor has a lot of competition to overcome in allegra, Claritin and other brands with a lot of satisfied patients. I used Seldane for years for my allergies and wouldn't have switched if it hadn't been for the harmful side affects. Levalbuterol will be going head to head against Albuterol period. Should be no contest in the long run. BAZER